DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Real-time Bid/Ask 08:24:54 2024-06-11 am EDT | ||
| 0.85 EUR / 0.94 EUR | +7.83% |
|
| Current month | +13.70% | ||
| 1 month | +50.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 0.84 | +1.20% |
| 24-06-10 | 0.83 | +7.79% |
| 24-06-07 | 0.77 | +4.05% |
| 24-06-06 | 0.74 | -1.33% |
| 24-06-05 | 0.75 | -10.71% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 05:29 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7K |
| ISIN | DE000MG0D7K7 |
| Date issued | 2024-03-18 |
| Strike | 375 $ |
| Maturity | 2025-03-21 (283 Days) |
| Parity | 10 : 1 |
| Emission price | 0.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.17 € |
|---|---|
| Lowest since issue | 0.51 € |
| Spread | 0.09 € |
| Spread % | 9.57% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
254.9
USD
Average target price
365.1
USD
Spread / Average Target
+43.23%
- Stock Market
- Certificates
- Certificat
